• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Acentra Health Welcomes Distinguished Public Sector Health Leaders Calder Lynch and Jami Snyder to its Healthcare Advisory Board; Appoints Julie Boughn as New Chair

    2/4/25 9:58:04 AM ET
    $CG
    Investment Managers
    Finance
    Get the next $CG alert in real time by email

    MCLEAN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, today announced the appointment of Calder Lynch and Jami Snyder to its healthcare advisory board. With decades of experience leading state and federal government healthcare programs, the subject matter experts will advise the company and its clients on healthcare policies and trends as well as strategies to improve health outcomes at a lower cost.

    "We are excited to welcome Calder Lynch and Jami Snyder to Acentra Health's Healthcare Advisory Board," said Todd Stottlemyer, CEO of Acentra Health. "Each brings decades of experience navigating and improving complex healthcare delivery systems across state and federal governments to successfully drive better outcomes in patient care. Their guidance will enhance our strategy to help our clients address their toughest challenges and deliver better health outcomes for the populations they serve."

    About Calder Lynch

    Calder Lynch is a nationally recognized healthcare executive with extensive experience leading transformative change in Medicaid and healthcare services. He brings expertise in strategy, public policy, and healthcare innovation. Lynch previously served as acting deputy administrator and chief of staff at the Centers for Medicare & Medicaid Services (CMS), as well as deputy administrator and director of the Center for Medicaid & CHIP (Children's Health Insurance Program) Services during President Trump's first term in office. While at CMS, Lynch led the early Medicaid COVID-19 response, rapidly deploying new policies and processes that enabled over 500 approvals of emergency actions aimed at supporting state efforts to increase telehealth access, streamline eligibility processes, and sustain community-based long-term-care providers. Prior to his federal service, Lynch held leadership roles as Medicaid director for Nebraska, as chief of staff for the Louisiana Department of Health and Hospitals, and as senior vice president at Commonwealth Care Alliance. He currently serves as vice president and regional Medicaid president for Humana in its Texas division.

    "I am pleased to join Acentra Health's Healthcare Advisory Board and collaborate with such a distinguished group of experts," said Lynch. "The company's mission aligns with my own passion for using emerging advances in technology to improve quality of care and efficiency in healthcare operations, and I look forward to helping Acentra Health address its clients' most complex challenges."

    About Jami Snyder

    Jami Snyder is a seasoned healthcare leader with more than 20 years of experience in public health and the private healthcare industry. Her expertise spans regulatory oversight, policy development, and leadership advisory services to states, payers, and providers. Snyder was appointed by Arizona Governor Doug Ducey to serve as the state's Medicaid director, holding that position for four years, where she led transformative initiatives to improve access and quality of care, particularly during the COVID-19 pandemic. Previously, Snyder served as associate commissioner for Medicaid/CHIP (Medicaid director) in Texas. She also served as president of the board for the National Association of Medicaid Directors (NAMD) and is a commissioner for the Medicaid and CHIP Payment and Access Commission (MACPAC), a non-partisan committee that advises Congress and state governments on policy and access issues related to Medicaid and CHIP. Snyder is currently president and CEO of JSN Strategies, LLC, a healthcare consultancy firm.

    "Acentra Health has a respected reputation as a trusted partner to state and federal clients for driving meaningful change that improves healthcare outcomes and delivers program value," said Snyder. "I look forward to contributing to the company's efforts to improve the quality and efficiency of healthcare delivery for healthcare consumers across the country."

    An additional change to the board includes the appointment of current board advisor Julie Boughn as chair. A former director of the Data and Systems Group for CMS's Center for Medicaid and CHIP Services (CMCS), Boughn joined the board in 2022 following an esteemed 30-year career in the health and information technology sectors. She specializes in data analysis, strategy, and Medicaid enterprise system modernization.

    In addition to advising Acentra Health's executive leaders, healthcare advisory board members serve as a vital resource to the company's portfolio of state, federal, and commercial clients. Members participate in regularly scheduled client focus group meetings, providing strategies for improving healthcare delivery and maximizing budget dollars. Advisory board members also support the company and its clients as subject matter experts, presenting at industry events and conferences. The nine-member board comprises experts across government, healthcare, and technology, including:

    • Dr. Raquel Bono – Retired Vice Admiral, U.S., Navy and former Director, Defense Health Agency.
    • Julie Boughn – Former Director, Data and Systems Group at the Center for Medicaid and CHIP Services within CMS, and healthcare technology innovator.
    • Aneesh Chopra – Chief Strategy Officer, Arcadia, and the nation's first U.S. Chief Technology Officer under President Obama.
    • Bobbie Greene Kilberg – Former President and CEO, Northern Virginia Technology Council, and technology policy expert.
    • Dr. Elder Granger – Retired Major General, U.S. Army, former Deputy Director/Program Executive Officer, TRICARE Management Activity, and President and CEO, THE 5Ps LLC, focusing on healthcare leadership.
    • Ryan Howells – Principal at Leavitt Partners and leading expert in healthcare data interoperability at the CARIN Alliance.
    • Charlies Milligan – CEO at Health Management Associates and former Medicaid Director for Maryland and New Mexico, with extensive policy and programmatic expertise.

    Read their bios and learn more acentra.com.

    About Acentra Health

    Acentra Health combines public sector knowledge, clinical expertise, and technological ingenuity to modernize the healthcare experience for state, federal, and commercial partners, and their priority populations. From designing and developing advanced claims, encounter, and provider solutions that drive efficiency and cost savings to delivering clinically focused service models for care management, clinical assessments, and quality oversight, Acentra Health is accelerating better health outcomes. Acentra Health is backed by Carlyle (NASDAQ:CG), a global investment firm. Learn more at acentra.com.

    Media Contact:

    Janice Moore

    Vice President, Corporate Communications

    703-214-3552

    Photos accompanying this announcement are available at: 

    https://www.globenewswire.com/NewsRoom/AttachmentNg/218de5be-f33a-48e4-92da-7b696ac3bea8

    https://www.globenewswire.com/NewsRoom/AttachmentNg/60097542-70e4-4621-a0fb-b76671d2027e

    https://www.globenewswire.com/NewsRoom/AttachmentNg/7c0f41f0-1e82-41b1-9565-8f06173c152e



    Primary Logo

    Get the next $CG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CG

    DatePrice TargetRatingAnalyst
    5/14/2025$56.00Hold → Buy
    TD Cowen
    3/19/2025Outperform → Perform
    Oppenheimer
    1/3/2025$60.00Peer Perform → Outperform
    Wolfe Research
    9/12/2024$42.00Equal Weight
    Wells Fargo
    8/27/2024$55.00Buy
    Redburn Atlantic
    8/6/2024$46.00 → $44.00Overweight → Neutral
    JP Morgan
    1/19/2024$40.00 → $41.00Buy → Neutral
    Citigroup
    1/4/2024$42.00Market Perform
    TD Cowen
    More analyst ratings

    $CG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Carlyle Group Inc. sold $100,225,698 worth of shares (3,671,271 units at $27.30) (SEC Form 4)

      4 - Carlyle Group Inc. (0001527166) (Reporting)

      6/2/25 4:30:39 PM ET
      $CG
      Investment Managers
      Finance
    • General Counsel Ferguson Jeffrey W. was granted 1,368 shares, increasing direct ownership by 0.12% to 1,097,293 units (SEC Form 4)

      4 - Carlyle Group Inc. (0001527166) (Issuer)

      5/29/25 5:09:59 PM ET
      $CG
      Investment Managers
      Finance
    • Chief Executive Officer Schwartz Harvey M was granted 31,709 shares, increasing direct ownership by 0.51% to 6,188,889 units (SEC Form 4)

      4 - Carlyle Group Inc. (0001527166) (Issuer)

      5/29/25 5:09:50 PM ET
      $CG
      Investment Managers
      Finance

    $CG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Trucordia to Receive $1.3 Billion Strategic Investment from Carlyle

      Transaction positions company for accelerated growth through improved capital structure and simplified governance LINDON, Utah and NEW YORK, June 4, 2025 /PRNewswire/ -- Trucordia today announced it will receive a $1.3 billion strategic investment from global investment firm Carlyle's Global Credit platform. The transaction will reduce Trucordia's leverage and simplify its governance structure by repurchasing units from existing minority investors. The transaction, which is expected to close this month and values Trucordia at $5.7 billion, provides the company with long-term

      6/4/25 7:00:00 AM ET
      $CG
      Investment Managers
      Finance
    • bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

      New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers bluebird bio (NASDAQ:BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital"). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer

      6/2/25 8:34:00 AM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

      All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025 Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") for either (x) $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right ("CVR") if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December

      5/30/25 8:30:00 AM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance

    $CG
    Leadership Updates

    Live Leadership Updates

    See more
    • SoftBank Group to Acquire Ampere Computing

      SoftBank Group Corp. (TSE: 9984, "SoftBank Group") today announced that it will acquire Ampere® Computing, a leading independent silicon design company, in an all-cash transaction valued at $6.5 billion. Under the terms of the agreement, Ampere will operate as a wholly owned subsidiary of SoftBank Group and retain its name. As part of the transaction, Ampere's lead investors – Carlyle (NASDAQ:CG) and Oracle Corp. (NYSE:ORCL) – are selling their respective positions in Ampere. As SoftBank Group broadens its AI infrastructure investments in ventures such as Cristal intelligence and Stargate, the acquisition will help enhance SoftBank Group's capabilities in key areas and accelerate its growt

      3/19/25 7:30:00 PM ET
      $CG
      $ORCL
      Investment Managers
      Finance
      Computer Software: Prepackaged Software
      Technology
    • Acentra Health Welcomes Distinguished Public Sector Health Leaders Calder Lynch and Jami Snyder to its Healthcare Advisory Board; Appoints Julie Boughn as New Chair

      MCLEAN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, today announced the appointment of Calder Lynch and Jami Snyder to its healthcare advisory board. With decades of experience leading state and federal government healthcare programs, the subject matter experts will advise the company and its clients on healthcare policies and trends as well as strategies to improve health outcomes at a lower cost. "We are excited to welcome Calder Lynch and Jami Snyder to Acentra Health's Healthcare Advisory Boar

      2/4/25 9:58:04 AM ET
      $CG
      Investment Managers
      Finance
    • Acentra Health Appoints Ezmeralda Sager as Chief Transformation Officer

      MCLEAN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced it has appointed Ezmeralda Sager as Executive Vice President and Chief Transformation Officer (CTO), effective January 6, 2025. In this role, Sager will spearhead enterprise-wide change initiatives to help Acentra Health build upon its strong track record of innovation and execution for its clients. She will provide strategic guidance on process improvements to optimize the development and delivery of the company's products, solutions

      1/23/25 9:42:00 AM ET
      $CG
      Investment Managers
      Finance

    $CG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Carlyle Group upgraded by TD Cowen with a new price target

      TD Cowen upgraded Carlyle Group from Hold to Buy and set a new price target of $56.00

      5/14/25 8:48:54 AM ET
      $CG
      Investment Managers
      Finance
    • Carlyle Group downgraded by Oppenheimer

      Oppenheimer downgraded Carlyle Group from Outperform to Perform

      3/19/25 8:14:15 AM ET
      $CG
      Investment Managers
      Finance
    • Carlyle Group upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Carlyle Group from Peer Perform to Outperform and set a new price target of $60.00

      1/3/25 7:19:04 AM ET
      $CG
      Investment Managers
      Finance

    $CG
    SEC Filings

    See more
    • The Carlyle Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders

      8-K - Carlyle Group Inc. (0001527166) (Filer)

      5/30/25 5:19:46 PM ET
      $CG
      Investment Managers
      Finance
    • Amendment: SEC Form SCHEDULE 13G/A filed by The Carlyle Group Inc.

      SCHEDULE 13G/A - Carlyle Group Inc. (0001527166) (Subject)

      5/13/25 11:44:13 AM ET
      $CG
      Investment Managers
      Finance
    • SEC Form 13F-HR filed by The Carlyle Group Inc.

      13F-HR - Carlyle Group Inc. (0001527166) (Filer)

      5/9/25 4:37:58 PM ET
      $CG
      Investment Managers
      Finance